At an Oct. 30 meeting related to Sydnexis’ formal dispute of an FDA complete response letter, advisory committee members ...

Dren Bio raised $350m, Pathos AI closed a $237m series E round and Warp Sciences emerged with $215m in recent venture ...

During the third quarter earnings call, the firm stressed it has the capacity for targeted dealmaking and wants to add in ...

Top leaders from companies large and small came together at the Oct. 29 Galien Forum in New York to share their insights ...

Summit’s ivonescimab and Roche’s giredestrant lead a 14-novel-agent lineup, where the FDA could reject nine and still beat ...

Medline has announced its exit from the bed market alongside an FDA safety alert detailing fire and entrapment hazards tied ...

Starting January 1, new maximum concentrations for aluminum in cosmetic products will come into effect for products sold in ...

The breast cancer drug represents a major launch for AstraZeneca, and a bellwether for pricing in the most favored nation era ...

Resmed’s Q1 revenue rose 6% to $1.4bn as sleep and mask sales grew, offsetting the Astral ventilator recall. With Astral ...

The French firm's priority is to protect earnings through Dupixent’s loss of exclusivity, but CFO François Roger tells Scrip ...

Stryker cut 2026 organic growth guidance to 6.5–7% as softer hip and knee procedure trends, vascular supply constraints and ...

The new US FDA facility lifecycle program under BsUFA IV will let biosimilar sponsors discuss manufacturing risks before ...